In addition, survival analysis stratified by cancer type revealed that NFE2L2 MU was associated with shorter OS in prostate cancer (HR: 3.02, 95% CI 1.25–7.30; Additional file 1: Fig. S3L) and NSCLC (HR: 1.57, 95% CI 1.28–1.94), while contrary association in endometrial cancer (HR: 0.27, 95% CI 0.13–0.58). Here, NFE2L2 is linked to prostate cancer.